-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MQGZzVfkY2K/BdWjr9QFfjdDNtK8f9qBPyMtVJX5MKV2bmy/5tZpSf9tq8Bzw0l/ Id4+wB/BrG9aN4i3Lm/79w== 0000891836-03-000543.txt : 20030919 0000891836-03-000543.hdr.sgml : 20030919 20030919170131 ACCESSION NUMBER: 0000891836-03-000543 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030331 FILED AS OF DATE: 20030919 EFFECTIVENESS DATE: 20030919 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 03903057 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 sc0278-03.txt FORM 13F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: March 31, 2003 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- -------------------------------------------- Form 13F File Number: 28-____________ The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-521-2418 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. September 19, 2003 - --------------------- -------------------- -------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [x] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ------------------ Form 13F Information Table Entry Total: 27 ------------------ Form 13F Information Table Entry Value: 222,153 ------------------ (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER NAME OF ISSUER TITLE OF CLASS CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS - -------------- -------------- ----- ------- ------- --- ---- ---------- -------- Autoimmune COM 052776101 18 26,100 SH SOLE Aclara Biosciences COM 00461P106 46 23,199 SH SOLE Amylin Pharmaceuticals COM 032346108 23,954 1,478,623 SH SOLE Alexion Pharmaceuticals COM 015351109 2,063 169,663 SH SOLE Alkermes COM 01642T108 726 80,095 SH SOLE Arena Pharmaceuticals COM 040047102 268 40,800 SH SOLE Exelixis COM 30161Q104 645 97,009 SH SOLE Gilead Sciences COM 375558103 1,884 44,876 SH SOLE Human Genome Sciences COM 444903108 1,796 210,000 SH SOLE Incyte COM 45337C102 4,999 1,671,870 SH SOLE Intrabiotics Pharmaceuticals COM 46116T506 135 644,290 SH SOLE Kosan Biosciences COM 50064W107 361 80,844 SH SOLE Neurocrine Biosciences COM 64125C109 1,754 42,100 SH SOLE Neurogen COM 64124E106 2,486 683,100 SH SOLE Pharmacyclics COM 716933106 75 22,300 SH SOLE Praecis Pharmaceuticals COM 739421105 200 50,100 SH SOLE Regeneron Pharmaceutical COM 75886F107 13,879 1,845,549 SH SOLE Symyx Technologies COM 87155S108 494 32,923 SH SOLE Tanox COM 87588Q109 1,075 83,039 SH SOLE Third Wave Technologies COM 88428W108 106 32,357 SH SOLE Trimeris COM 896263100 136,422 3,316,052 SH SOLE Tularik COM 899165104 760 150,502 SH SOLE Ventiv Health COM 922793104 64 27,300 SH SOLE Incyte Notes 5.5% 3/01/2007 CONV BONDS 45337CAC6 3,444 5,000,000 PRN SOLE Alkermes Conv Notes 6.52% 12/31/09 CONV BONDS 01642TAC2 7,634 5,572,000 PRN SOLE Aviron Conv Notes CONV BONDS 053762AD2 2,070 2,000,000 PRN SOLE Regeneron Pharmaceuticals Conv Notes 5.5% 10/17/08 (144A) CONV BONDS 75886FAB3 14,795 21,060,000 PRN SOLE ------- 222,153 =======
COLUMN 8 VOTING AUTHORITY NAME OF ISSUER SOLE SHARED NONE - -------------- ---- ------ ---- Autoimmune 26,100 Aclara Biosciences 23,199 Amylin Pharmaceuticals 1,478,623 Alexion Pharmaceuticals 169,663 Alkermes 80,095 Arena Pharmaceuticals 40,800 Exelixis 97,009 Gilead Sciences 44,876 Human Genome Sciences 210,000 Incyte 1,671,870 Intrabiotics Pharmaceuticals 644,290 Kosan Biosciences 80,844 Neurocrine Biosciences 42,100 Neurogen 683,100 Pharmacyclics 22,300 Praecis Pharmaceuticals 50,100 Regeneron Pharmaceutical 1,845,549 Symyx Technologies 32,923 Tanox 83,039 Third Wave Technologies 32,357 Trimeris 3,316,052 Tularik 150,502 Ventiv Health 27,300 Incyte Notes 5.5% 3/01/2007 5,000,000 Alkermes Conv Notes 6.52% 12/31/09 5,572,000 Aviron Conv Notes 2,000,000 Regeneron Pharmaceuticals Conv Notes 5.5% 10/17/08 (144A) 21,060,000
-----END PRIVACY-ENHANCED MESSAGE-----